Methods for inducing in vivo tolerance
The present invention encompasses methods for inducing in vivo tolerance to a foreign tissue.
1. A method for inducing in vivo tolerance to a foreign organ in a subject, the method comprising administering an agonistic anti-BTLA antibody that does not deplete T cells to a subject undergoing solid organ transplant at substantially the same time as the foreign organ exposure.
2. The method of claim 1 , wherein the immune system of the subject is not systemically suppressed.
3. The method of claim 1 , wherein the antibody is administered at the same time as the foreign organ exposure.
4. The method of claim 1 , wherein the antibody is administered within one week of the foreign organ exposure.
5. The method of claim 1 , wherein the antibody is administered before foreign organ exposure.
6. The method of claim 1 , wherein the antibody expands a pre-existing Treg cell population.
7. The method of claim 1 , wherein the antibody is administered once.
8. The method of claim 7 , wherein the antibody is administered once, and at the time of foreign organ exposure.
9. A method for treating GVHD, the method comprising administering an agonistic anti-BTLA antibody that does not deplete T cells to a subject undergoing solid organ transplant at substantially the same time as the subject is exposed to a graft.
10. The method of claim 9 , wherein the antibody is administered at the same time as the graft exposure.
11. The method of claim 9 , wherein the antibody is administered before graft exposure.
12. The method of claim 9 , wherein the antibody is administered within one week of the graft exposure.
13. The method of claim 9 , wherein the antibody expands a pre-existing Treg cell population.
14. The method of claim 9 , wherein the antibody is administered once.
15. The method of claim 14 , wherein the antibody is administered once, and at the time of graft exposure.
16. A method to increase the number of Treg cells in a subject, the method comprising administering an agonistic anti-BTLA antibody that does not deplete T cells to a subject at substantially the same time the subject is exposed to a graft.
17. The method of claim 16 , wherein the Treg cells are donor-derived.
18. The method of claim 16 , wherein the Treg cells are pre-existing.
19. The method of claim 16 , wherein the antibody is administered at the same time as the graft exposure.
20. The method of claim 16 , wherein the antibody is administered before graft exposure.
21. The method of claim 16 , wherein the antibody is administered within one week of the graft exposure.
22. The method of claim 16 , wherein the antibody is administered once.
23. The method of claim 22 , wherein the antibody is administered once, and at the time of graft exposure.